Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Research & Development (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Research & Development for 11 consecutive years, with $615.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 13.54% to $615.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Dec 2025, up 9.86% year-over-year, with the annual reading at $2.1 billion for FY2025, 9.86% up from the prior year.
  • Research & Development for Q4 2025 was $615.4 million at BeOne Medicines, up from $523.7 million in the prior quarter.
  • The five-year high for Research & Development was $615.4 million in Q4 2025, with the low at -$556.3 million in Q4 2021.
  • Average Research & Development over 5 years is $399.5 million, with a median of $449.6 million recorded in 2022.
  • The sharpest move saw Research & Development plummeted 256.46% in 2021, then surged 180.18% in 2022.
  • Over 5 years, Research & Development stood at -$556.3 million in 2021, then skyrocketed by 180.18% to $446.0 million in 2022, then rose by 10.75% to $494.0 million in 2023, then rose by 9.72% to $542.0 million in 2024, then increased by 13.54% to $615.4 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $615.4 million, $523.7 million, and $524.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.